These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including:
- A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002).
- Review of key literature, especially randomized study results, but also Medline, Internet, Cochrane database searches, and prior guidelines (Br J Haematol 115: 522-540, 2001).
- Feedback from patients participating in the International Myeloma Foundation, patient
These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. ‘Consensus’ reflects general, although not necessarily unanimous, agreement. Details are discussed as appropriate. For convenience, the recommendations are divided into:
- Staging and prognostic
- High-dose therapy and
- Supportive care and management of specific
- Novel therapies and new
Brian GM Durie, Robert A Kyle, Andrew Belch, William Bensinger, Joan Blade, Mario Boccadoro, J Anthony Child, Raymond Comenzo, Ben Djulbegovic, Dorotea Fantl, Gosta Gahrton, Jean-Luc Harousseau, Vania Hungria, Douglas Joshua, Heinz Ludwig, Jayesh Mehta, Angelina Rodriquez- Morales, Gareth Morgan, Amara Nouel, Martin Oken, Raymond Powles, David Roodman, Jesus San Miguel, Kazuyuki Shimizu, Seema Singhal, Bhawna Sirohi, Pieter Sonneveld, Guido Tricot and Brian Van Ness.
The Hematology Journal (2003) 4, 379-398. doi:l0.1038/sj.thj.6200312